GlaxoSmithKline PLC’s plan to form a consumer health joint venture with Pfizer Inc. has caught the eye of Australia’s Competition and Consumer Commission, which has initiated an informal review of the proposed deal to assess whether it is “likely to have the effect of substantially lessening competition” in the country’s consumer health market.
The ACCC is inviting interested parties to comment on the deal – particularly on overlaps between GSK’s and Pfizer’s respective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?